Soleno Therapeutics (SLNO) Competitors $44.74 -0.44 (-0.97%) (As of 12:58 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SLNO vs. GKOS, BLCO, INSP, PRCT, AXNX, NVCR, NVST, NARI, IRTC, and LIVNShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), NovoCure (NVCR), Envista (NVST), Inari Medical (NARI), iRhythm Technologies (IRTC), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Soleno Therapeutics vs. Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics NovoCure Envista Inari Medical iRhythm Technologies LivaNova Glaukos (NYSE:GKOS) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Does the media prefer GKOS or SLNO? In the previous week, Glaukos had 9 more articles in the media than Soleno Therapeutics. MarketBeat recorded 15 mentions for Glaukos and 6 mentions for Soleno Therapeutics. Glaukos' average media sentiment score of 0.95 beat Soleno Therapeutics' score of 0.87 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 6 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is GKOS or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Glaukos' net margin of -42.43%. Glaukos' return on equity of -18.99% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Glaukos-42.43% -18.99% -11.47% Soleno Therapeutics N/A -61.99%-55.21% Do analysts prefer GKOS or SLNO? Glaukos currently has a consensus price target of $145.92, indicating a potential downside of 2.27%. Soleno Therapeutics has a consensus price target of $74.83, indicating a potential upside of 67.26%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Glaukos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has preferable valuation and earnings, GKOS or SLNO? Soleno Therapeutics has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlaukos$360.35M22.85-$134.66M-$3.02-49.44Soleno TherapeuticsN/AN/A-$38.99M-$3.32-13.48 Which has more volatility & risk, GKOS or SLNO? Glaukos has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.47, meaning that its share price is 247% less volatile than the S&P 500. Does the MarketBeat Community believe in GKOS or SLNO? Glaukos received 135 more outperform votes than Soleno Therapeutics when rated by MarketBeat users. However, 72.09% of users gave Soleno Therapeutics an outperform vote while only 64.77% of users gave Glaukos an outperform vote. CompanyUnderperformOutperformGlaukosOutperform Votes44564.77% Underperform Votes24235.23% Soleno TherapeuticsOutperform Votes31072.09% Underperform Votes12027.91% Do institutionals & insiders hold more shares of GKOS or SLNO? 99.0% of Glaukos shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 6.4% of Glaukos shares are owned by company insiders. Comparatively, 12.3% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryGlaukos beats Soleno Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93B$3.12B$5.17B$9.13BDividend YieldN/A1.77%5.12%4.26%P/E Ratio-13.4817.0387.6817.15Price / SalesN/A51.181,139.10118.46Price / CashN/A39.9343.2337.85Price / Book8.673.764.784.78Net Income-$38.99M$89.83M$120.55M$225.50M7 Day Performance-6.66%-1.57%-1.47%-1.00%1 Month Performance-22.57%-2.00%14.33%0.67%1 Year Performance18.08%-1.26%29.21%15.58% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.4783 of 5 stars$44.74-1.0%$74.83+67.3%+19.2%$1.93BN/A-13.4830GKOSGlaukos4.1307 of 5 stars$143.87+3.6%$143.17-0.5%+83.3%$7.93B$360.35M-46.00780BLCOBausch + Lomb3.0868 of 5 stars$18.62+0.1%$20.58+10.5%+13.9%$6.56B$4.68B-17.7113,300Positive NewsINSPInspire Medical Systems4.8769 of 5 stars$187.26-0.3%$233.58+24.7%-3.9%$5.61B$755.59M176.781,011Positive NewsGap DownPRCTPROCEPT BioRobotics2.8261 of 5 stars$89.54+0.3%$97.86+9.3%+92.9%$4.67B$136.19M0.00626Positive NewsAXNXAxonics1.412 of 5 stars$70.98+0.8%$71.00+0.0%+13.5%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.5011 of 5 stars$32.84-1.7%$32.67-0.5%+131.6%$3.55B$577.74M-23.861,453NVSTEnvista4.0439 of 5 stars$19.59+0.6%$20.65+5.4%-22.7%$3.37B$2.50B-2.5112,800NARIInari Medical3.3249 of 5 stars$55.39-0.4%$58.89+6.3%-15.6%$3.24B$574.50M-41.181,300Insider TradeIRTCiRhythm Technologies2.9257 of 5 stars$89.50+3.6%$107.82+20.5%-15.6%$2.80B$492.68M-17.782,000LIVNLivaNova3.2104 of 5 stars$50.15-2.6%$69.17+37.9%-8.1%$2.72B$1.24B122.622,900Positive News Related Companies and Tools Related Companies Glaukos Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives PROCEPT BioRobotics Alternatives Axonics Alternatives NovoCure Alternatives Envista Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives LivaNova Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLNO) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
